A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon [PF-01913539] On The Single-Dose Pharmacokinetics Of The CYP2D6 Substrate Dextromethorphan In Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 15 Jan 2010
At a glance
- Drugs Dextromethorphan; Latrepirdine
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 05 Mar 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jan 2009 Actual initiation date (Nov 2008) added as reported by ClinicalTrials.gov.